12 Month Price Forecast For IVA
Distance to IVA Price Forecasts
IVA Price Momentum
๐ค Considering Inventiva (IVA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 3:50 AM UTC
IVA Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, IVA has a consensus that is bullish. The median price target is $12.50, with forecasts ranging from $3.00 to $20.00. Currently, there are 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings.
With IVA currently trading at $2.43, the median price forecast suggests a 413.8% upside. The most optimistic forecast comes from Annabel Samimy at Stifel, projecting a 722.0% upside, while at provides the most conservative target, suggesting a 23.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IVA Analyst Consensus
IVA Price Target Range
Latest IVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IVA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 30, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
Nov 22, 2024 | Stifel | Annabel Samimy | Buy | Maintains | $17.00 |
Nov 12, 2024 | UBS | Eliana Merle | Neutral | Initiates | $3.00 |
Oct 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $13.00 |
Sep 26, 2024 | Stifel | Annabel Samimy | Buy | Maintains | $20.00 |
Sep 26, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $14.00 |
Sep 26, 2024 | HC Wainwright& Co. | Buy | Maintains | $0.00 | |
Apr 8, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $20.00 |
Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $22.00 |
Mar 20, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $22.00 |
Mar 8, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $22.00 |
Feb 16, 2024 | Stifel | Annabel Samimy | Buy | Maintains | $25.00 |
Dec 21, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $24.00 |
Oct 27, 2023 | Canaccord Genuity | Edward Nash | Buy | Initiates | $12.00 |
Sep 21, 2023 | Roth MKM | Dylan Dupuis | Buy | Reiterates | $11.00 |
Sep 1, 2023 | Guggenheim | Etzer Darout | Buy | Reiterates | $12.00 |
Jul 28, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
Jun 16, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $35.00 |
May 31, 2023 | Roth MKM | Dylan Dupuis | Buy | Initiates | $11.00 |
May 26, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $35.00 |
Stocks Similar to Inventiva S.A.
The following stocks are similar to Inventiva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inventiva S.A. (IVA) Financial Data
Inventiva S.A. has a market capitalization of $222.56M with a P/E ratio of -1.0x. The company generates $19.90M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -58.7% quarter-over-quarter, while maintaining an operating margin of -1,911.1% and return on equity of +344.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Inventiva S.A. (IVA) Company Overview
About Inventiva S.A.
Develops therapies for liver and rare diseases.
Inventiva S.A. focuses on creating oral small molecule therapies targeting specific diseases, primarily non-alcoholic steatohepatitis (NASH) and rare genetic disorders. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapies once they receive regulatory approval.
Founded in 2011 and headquartered in Daix, France, Inventiva is currently advancing its lead product candidate, Lanifibranor, in Phase III clinical trials. The company also has a pipeline that includes Odiparcil for mucopolysaccharidosis type VI and various earlier-stage programs in oncology and other therapeutic areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
123
CEO
Mr. Frederic Cren
Country
France
IPO Year
2020
Website
www.inventivapharma.comInventiva S.A. (IVA) Latest News & Analysis
Inventiva announced positive results from a clinical study on lanifibranor for treating type 2 diabetes and metabolic liver disease, showing significant improvements in insulin resistance.
Positive clinical trial results for lanifibranor could enhance Inventiva's market position, potentially boosting stock value and attracting investor interest in the biopharmaceutical sector.
Inventiva, a clinical-stage biopharmaceutical company, reported on its liquidity contract with Kepler Cheuvreux in its half-year update, focusing on therapies for metabolic dysfunction-related diseases.
The liquidity contract report indicates Inventiva's financial health and market activity, which can influence stock performance and investor confidence in the company's future.
Inventiva will present Proof-of-Concept trial results for lanifibranor and empagliflozin in treating MASH at the SLD Summit 2025, hosted by EASL from January 23-25 in Portugal.
The presentation of positive trial results at a major medical conference can boost Inventiva's credibility and attract investor interest, potentially impacting stock performance and partnerships.
Inventiva announced it will issue โฌ21.4 million in the second phase of its multi-tranche equity financing, totaling up to โฌ348 million, to support its biopharmaceutical development.
The announcement of a โฌ21.4 million capital raise indicates strong investor interest and funding for Inventiva's clinical projects, potentially enhancing growth prospects and stock value.
Inventiva (IVA), a biopharmaceutical firm focused on treatments for NASH, will present at the J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.
Inventiva's presentation at a major healthcare conference highlights its focus on a significant market (NASH) and potential investor interest, impacting stock performance and market perception.
Inventiva announced the results of its Combined Shareholders' Meeting on December 11, 2024. The company focuses on developing therapies for MASH/NASH and other unmet medical needs.
The outcome of the shareholders' meeting could impact company strategy and future funding, influencing Inventiva's stock performance and investor sentiment in the biopharmaceutical sector.
Frequently Asked Questions About IVA Stock
What is Inventiva S.A.'s (IVA) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Inventiva S.A. (IVA) has a median price target of $12.50. The highest price target is $20.00 and the lowest is $3.00.
Is IVA stock a good investment in 2025?
According to current analyst ratings, IVA has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for IVA stock?
Wall Street analysts predict IVA stock could reach $12.50 in the next 12 months. This represents a 413.8% increase from the current price of $2.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inventiva S.A.'s business model?
Inventiva S.A. focuses on creating oral small molecule therapies targeting specific diseases, primarily non-alcoholic steatohepatitis (NASH) and rare genetic disorders. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapies once they receive regulatory approval.
What is the highest forecasted price for IVA Inventiva S.A.?
The highest price target for IVA is $20.00 from Annabel Samimy at Stifel, which represents a 722.0% increase from the current price of $2.43.
What is the lowest forecasted price for IVA Inventiva S.A.?
The lowest price target for IVA is $3.00 from at , which represents a 23.5% increase from the current price of $2.43.
What is the overall IVA consensus from analysts for Inventiva S.A.?
The overall analyst consensus for IVA is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $12.50.
How accurate are IVA stock price projections?
Stock price projections, including those for Inventiva S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.